Form 4: Phreesia SVP David Linetsky Sells Shares Under 10b5-1 Trading Plan

David Linetsky, SVP of Life Sciences at Phreesia, Inc., sold 300 shares of common stock at an average price of $29.5233 under a pre-arranged 10b5-1 trading plan.

Summary

• On February 7, 2025, David Linetsky, SVP of Life Sciences at Phreesia, Inc., sold 300 shares of common stock.
• The sale was executed at a weighted average price of $29.5233 per share, with individual prices ranging from $29.50 to $29.55.
• The transaction was conducted under a Rule 10b5-1 trading plan adopted on July 18, 2024.
• Following the transaction, Linetsky directly owns 229,751 shares and indirectly owns 8,851 shares through his spouse.

Sentiment

Score: 5

Explanation: The document is a routine regulatory filing detailing a stock sale by an executive under a pre-arranged trading plan. It doesn't inherently indicate positive or negative sentiment.

Industry Context

Form 4 filings are standard practice and provide transparency into the transactions of company insiders. The use of a 10b5-1 trading plan suggests the insider planned the transaction in advance to avoid accusations of trading on inside information.

Stakeholder Impact

• The stock sale by a company executive could be perceived neutrally or slightly negatively by shareholders, depending on their interpretation of the executive's motivations.

Key Dates

Keywords

Phreesia, David Linetsky, stock sale, Form 4, 10b5-1 trading plan, insider trading, securities, ownership